Concord Biotech Ltd. (CONCORDBIO) Price & Analysis

Compare

2 Followers

CONCORDBIO Stock Chart & Stats

₹1338.60

₹62.10(2.74%)

At close: Jan 09 4:00 PM EST

₹1338.60

₹62.10(2.74%)

Day’s Range― - ―

52-Week Range₹1,056.75 - ₹2,149.90

Previous CloseN/A

Volume295.44K

Average Volume (3M)12.81K

Market Cap

₹118.16B

Enterprise Value₹117.98B

Total Cash (Recent Filing)₹3.81B

Total Debt (Recent Filing)₹16.07M

Price to Earnings (P/E)54.6

Beta1.02

Next Earnings

May 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.8%

Share Statistics

EPS (TTM)6.30

Shares Outstanding104,616,200

10 Day Avg. Volume31,605

30 Day Avg. Volume12,808

Financial Highlights & Ratios

PEG Ratio2.27

Price to Book (P/B)9.60

Price to Sales (P/S)14.50

P/FCF Ratio127.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)30.08

Revenue Forecast (FY)₹12.66B

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetLow financial leverage and a high equity ratio provide durable financial flexibility. This supports long-term investments in fermentation capacity, absorption of regulatory or demand shocks, and the ability to fund process development or M&A without stressing cash flows, improving resilience.

Healthy Cash GenerationConsistent positive operating cash flow demonstrates reliable cash conversion from profitable operations, enabling sustained capex for complex API manufacturing, working-capital funding, and reinvestment into process scale-ups. This underpins execution of long-term growth initiatives.

Robust Profitability And Revenue GrowthSustained revenue increases and solid margins reflect efficiency in complex fermentation-based API manufacturing. High profitability supports reinvestment in specialized capabilities and gives pricing headroom versus commoditized peers, sustaining competitive advantage over time.

Bears Say

Inconsistent Free Cash Flow & Margin PressureFluctuating free cash flow complicates steady funding of capital-intensive fermentation assets and process development. Slight declines in gross margin suggest raw-material, yield, or pricing pressure that could erode long-term profitability if not addressed through efficiency or product mix shifts.

Customer/product Concentration RiskReliance on a limited set of large customers or a narrow product portfolio increases revenue volatility and bargaining risk. Losing a major contract or facing demand changes for key APIs would meaningfully affect utilization, margins, and growth visibility over several quarters to years.

Regulatory And Market Access DependencyExport approvals and regulatory compliance are structural dependencies for API suppliers. Delays, inspections, or changing foreign regulations can restrict market access, delay shipments, and reduce capacity utilization, creating persistent operational and revenue risk if compliance costs rise.

Concord Biotech Ltd. News

Concord Biotech Updates Key Managerial Authorisations for Market Disclosures

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) has shared an announcement. Concord Biotech Limited has revised the list of...

3M ago

Mycophenolate Pregnancy Registry: Key Insights for Investors

Amneal Pharma (($AMRX)), Sandoz Group Ltd (($SDZXF)), Alkem Laboratories Ltd. (($IN:ALKEM)), Concord Biotech Ltd. (($IN:CONCORDBIO)) announced an update...

5M ago

AMRX

Concord Biotech Releases Q1 2025 Financial Results

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) has issued an update. Concord Biotech Ltd. has released an investor presentation...

7M ago

Concord Biotech Releases Q3 2025 Earnings Call Transcripts

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) just unveiled an announcement. Concord Biotech Limited has made available the transcripts...

1y ago

CONCORDBIO FAQ

What was Concord Biotech Ltd.’s price range in the past 12 months?

Concord Biotech Ltd. lowest stock price was ₹1056.75 and its highest was ₹2149.90 in the past 12 months.

What is Concord Biotech Ltd.’s market cap?

Concord Biotech Ltd.’s market cap is ₹118.16B.

When is Concord Biotech Ltd.’s upcoming earnings report date?

Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is in 64 days.

How were Concord Biotech Ltd.’s earnings last quarter?

Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.

Is Concord Biotech Ltd. overvalued?

According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Concord Biotech Ltd. pay dividends?

Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here

What is Concord Biotech Ltd.’s EPS estimate?

Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Concord Biotech Ltd. have?

Concord Biotech Ltd. has 104,616,200 shares outstanding.

What happened to Concord Biotech Ltd.’s price movement after its last earnings report?

Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.

Which hedge fund is a major shareholder of Concord Biotech Ltd.?

Currently, no hedge funds are holding shares in IN:CONCORDBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Concord Biotech Ltd.

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.